Cover Image
Market Research Report

Pneumococcal Vaccines Market and Forecast Analysis to 2022

Published by Datamonitor Healthcare Product code 365204
Published Content info 145 Pages
Delivery time: 1-2 business days
Price
Back to Top
Pneumococcal Vaccines Market and Forecast Analysis to 2022
Published: December 21, 2018 Content info: 145 Pages
Description

OVERVIEW

Streptococcus pneumoniae is a major cause of morbidity and mortality worldwide, with an estimated 1.6 million people dying of invasive pneumococcal disease (IPD) each year. IPD primarily comprises septicemia, pneumonia, and meningitis. However, S. pneumoniae infections can also lead to other diseases such as bronchitis or pericarditis. IPD occurs most commonly among the very young (<24 months) and the elderly (>65 years); the elderly have the highest IPD mortality rates.

MARKET SNAPSHOT

  • Market growth will be maintained by price rises, increased vaccination uptake in the elderly, and a stable infant population.
  • Prevnar 13 will continue to dominate US and EU markets, but pipeline vaccines could pose formidable threats from 2022. V114 and GSK-3 will threaten the dominance of Prevnar 13 with potential for broader coverage, starting in 2022.
Table of Contents
Product Code: DMKC10636

TABLE OF CONTENTS

FORECAST: PNEUMOCOCCAL VACCINES (Published on 21 December 2018)

  • OVERVIEW
  • FORECAST AND FUTURE TRENDS
  • MARKET DEFINITION AND METHODOLOGY
  • PRIMARY RESEARCH METHODOLOGY
  • US MARKET FORECAST
  • JAPAN MARKET FORECAST
  • FRANCE MARKET FORECAST
  • GERMANY MARKET FORECAST
  • ITALY MARKET FORECAST
  • SPAIN MARKET FORECAST
  • UK MARKET FORECAST
  • PRODUCT PROFILE: PNEUMOVAX 23
  • PRODUCT PROFILE: PREVNAR 13
  • PRODUCT PROFILE (LATE STAGE): V114

MARKETED DRUGS: PNEUMOCOCCAL VACCINES (Published on 21 December 2018)

  • OVERVIEW
  • PRODUCT OVERVIEW
  • PRODUCT PROFILE: PNEUMOVAX 23
  • PRODUCT PROFILE: PREVNAR 13
  • PRODUCT PROFILE: SYNFLORIX

PIPELINE: PNEUMOCOCCAL VACCINES (Published on 21 December 2018)

  • OVERVIEW
  • CLINICAL PIPELINE OVERVIEW
  • PRODUCT PROFILE (LATE STAGE): GSK-3
  • PRODUCT PROFILE (LATE STAGE): PF-06482077
  • PRODUCT PROFILE (LATE STAGE): V114

LIST OF FIGURES

  • Figure 1: Total sales of pneumococcal vaccines across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 2: Total sales of pneumococcal vaccines across the US, Japan, and five major EU markets, by risk group, 2017-26
  • Figure 3: Total sales of pneumococcal vaccines in the US, by risk group, 2017-26
  • Figure 4: Total sales of pneumococcal vaccines in the five major EU markets, by brand, 2017-26
  • Figure 5: Total sales of pneumococcal vaccines in Japan, by brand, 2017-26
  • Figure 6: Total sales of pneumococcal vaccines across the US, Japan, and five major EU markets, by brand, 2017-26
  • Figure 7: Patient-based forecasting methodology for pneumococcal vaccines
  • Figure 8: Price sources and calculations, by country
  • Figure 9: Total sales of pneumococcal vaccines in the US, by brand, 2017-26
  • Figure 10: Total sales of pneumococcal vaccines in the US, by risk group, 2017-26
  • Figure 11: Pneumococcal vaccination coverage in the US, by risk group, 2017-26
  • Figure 12: Total sales of pneumococcal vaccines in Japan, by brand, 2017-26
  • Figure 13: Total sales of pneumococcal vaccines in Japan, by risk group, 2017-26
  • Figure 14: Pneumococcal vaccination coverage in Japan, by risk group, 2017-26
  • Figure 15: Total sales of pneumococcal vaccines in France, by risk group, 2017-26
  • Figure 16: Total sales of pneumococcal vaccines in France, by brand, 2017-26
  • Figure 17: Pneumococcal vaccination coverage in France, by risk group, 2017-26
  • Figure 18: Total sales of pneumococcal vaccines in Germany, by brand, 2017-26
  • Figure 19: Total sales of pneumococcal vaccines in Germany, by risk group, 2017-26
  • Figure 20: Pneumococcal vaccination coverage in Germany, by risk group, 2017-26
  • Figure 21: Total sales of pneumococcal vaccines in Italy, by brand, 2017-26
  • Figure 22: Total sales of pneumococcal vaccines in Italy, by risk group, 2017-26
  • Figure 23: Pneumococcal vaccination coverage in Italy, by risk group, 2017-26
  • Figure 24: Total sales of pneumococcal vaccines in Spain, by risk group, 2017-26
  • Figure 25: Total sales of pneumococcal vaccines in Spain, by brand, 2017-26
  • Figure 26: Pneumococcal vaccination coverage in Spain, by risk group, 2017-26
  • Figure 27: Total sales of pneumococcal vaccines in the UK, by brand, 2017-26
  • Figure 28: Pneumococcal vaccination coverage in the UK, by risk group, 2017-26
  • Figure 29: Pneumovax 23 sales for pneumococcal vaccination across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 30: Prevnar 13 sales for pneumococcal vaccination across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 31: V114 sales for pneumococcal vaccination across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 32: Pneumovax 23 sales for pneumococcal vaccination across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 33: Prevnar 13 sales for pneumococcal vaccination across the US, Japan, and five major EU markets, by country, 2017-26
  • Figure 34: V114 sales for pneumococcal vaccination across the US, Japan, and five major EU markets, by country, 2017-26

LIST OF TABLES

  • Table 1: Recommendations for pneumococcal vaccination by national authorities, 2018
  • Table 2: Exchange rates used for calculating prices
  • Table 3: Pneumovax 23 drug profile
  • Table 4: Approval history of Pneumovax 23 for pneumococcal vaccination in the US, Japan, and five major EU markets
  • Table 5: Pneumococcal vaccine recommendations for Pneumovax 23, by country and age group
  • Table 6: Late-phase trials of Pneumovax 23 for pneumococcal vaccination
  • Table 7: Pneumovax 23 for pneumococcal vaccination - SWOT analysis
  • Table 8: Prevnar 13 drug profile
  • Table 9: Approval history of Prevnar 13 for pneumococcal vaccination in the US, Japan, and five major EU markets
  • Table 10: Pneumococcal vaccine recommendations for Prevnar 13, by country and age group
  • Table 11: Late-phase trials of Prevnar 13 for pneumococcal vaccination
  • Table 12: Prevnar 13 for pneumococcal vaccination - SWOT analysis
  • Table 13: V114 drug profile
  • Table 14: Trials of V114 for pneumococcal vaccination
  • Table 15: V114 for pneumococcal vaccination - SWOT analysis
  • Table 16: Profiled key marketed drugs for pneumococcal disease
  • Table 17: Pneumovax 23 drug profile
  • Table 18: Approval history of Pneumovax 23 for pneumococcal vaccination in the US, Japan, and five major EU markets
  • Table 19: Pneumococcal vaccine recommendations for Pneumovax 23, by country and age group
  • Table 20: Late-phase trials of Pneumovax 23 for pneumococcal vaccination
  • Table 21: Pneumovax 23 for pneumococcal vaccination - SWOT analysis
  • Table 22: Prevnar 13 drug profile
  • Table 23: Approval history of Prevnar 13 for pneumococcal vaccination in the US, Japan, and five major EU markets
  • Table 24: Pneumococcal vaccine recommendations for Prevnar 13, by country and age group
  • Table 25: Late-phase trials of Prevnar 13 for pneumococcal vaccination
  • Table 26: Prevnar 13 for pneumococcal vaccination - SWOT analysis
  • Table 27: Synflorix drug profile
  • Table 28: Approval history of Synflorix for pneumococcal vaccination in Japan and the five major EU markets
  • Table 29: Late-phase trials of Synflorix for pneumococcal vaccination
  • Table 30: Synflorix for pneumococcal vaccination - SWOT analysis
  • Table 31: Profiled key late-stage pipeline products for pneumococcal vaccination
  • Table 32: GSK-3 drug profile
  • Table 33: Trials of GSK-3 for pneumococcal vaccination
  • Table 34: GSK-3 for pneumococcal vaccination - SWOT analysis
  • Table 35: PF-06482077 drug profile
  • Table 36: Trials of PF-06482077 for pneumococcal vaccination
  • Table 37: PF-06482077 for pneumococcal vaccination - SWOT analysis
  • Table 38: V114 drug profile
  • Table 39: Trials of V114 for pneumococcal vaccination
  • Table 40: V114 for pneumococcal vaccination - SWOT analysis
Back to Top